

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11462371/publications.pdf>

Version: 2024-02-01

70  
papers

5,377  
citations

70961

41  
h-index

102304

66  
g-index

70  
all docs

70  
docs citations

70  
times ranked

3450  
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictors of long-term cryoglobulinemic vasculitis outcomes after HCV eradication with direct-acting antivirals in the real-life. <i>Autoimmunity Reviews</i> , 2022, 21, 102923.	2.5	10
2	A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort. <i>Hepatology</i> , 2022, 76, 220-232.	3.6	12
3	B-cell activating factor (BAFF), BAFF promoter and BAFF receptor allelic variants in hepatitis C virus related Cryoglobulinemic Vasculitis and Non-Hodgkin's Lymphoma. <i>Hematological Oncology</i> , 2022, , .	0.8	4
4	Solving the mystery of HBV-related mixed cryoglobulinemia: potential biomarkers of disease progression. <i>Rheumatology</i> , 2021, 60, 4418-4427.	0.9	4
5	Hepatitis B Virus-Related Cryoglobulinemic Vasculitis: Review of the Literature and Long-Term Follow-Up Analysis of 18 Patients Treated with Nucleos(t)ide Analogues from the Italian Study Group of Cryoglobulinemia (GISC). <i>Viruses</i> , 2021, 13, 1032.	1.5	19
6	Hematological and Genetic Markers in the Rational Approach to Patients With HCV Sustained Virological Response With or Without Persisting Cryoglobulinemic Vasculitis. <i>Hepatology</i> , 2021, 74, 1164-1173.	3.6	10
7	Expert Opinion on Managing Chronic HCV in Patients with Mixed Cryoglobulinaemia Vasculitis. <i>Antiviral Therapy</i> , 2018, 23, 1-9.	0.6	10
8	Editorial: interferon-free DAAs are a great boon for patients with hepatitis C and cryoglobulinaemia—Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 772-773.	1.9	0
9	Cryoglobulinaemia. <i>Nature Reviews Disease Primers</i> , 2018, 4, 11.	18.1	143
10	Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 2017, 66, 1282-1299.	1.8	73
11	International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. <i>Autoimmunity Reviews</i> , 2017, 16, 523-541.	2.5	87
12	Hepatitis B virus related cryoglobulinemic vasculitis: A multicentre open label study from the Gruppo Italiano di Studio delle Crioglobulinemie "GISC. <i>Digestive and Liver Disease</i> , 2016, 48, 780-784.	0.4	50
13	Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia. <i>Hepatology</i> , 2016, 64, 1473-1482.	3.6	167
14	International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. <i>Autoimmunity Reviews</i> , 2016, 15, 1145-1160.	2.5	87
15	Assessment of free light chains in HCV-positive patients with mixed cryoglobulinaemia vasculitis undergoing rituximab treatment. <i>Liver International</i> , 2015, 35, 2100-2107.	1.9	17
16	HCV syndrome: A constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin's lymphoma, and cancer. <i>World Journal of Hepatology</i> , 2015, 7, 327.	0.8	118
17	Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic review. <i>Autoimmunity Reviews</i> , 2015, 14, 889-896.	2.5	53
18	Virus-driven autoimmunity and lymphoproliferation: the example of HCV infection. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 15-31.	1.3	73

#	ARTICLE	IF	CITATIONS
19	Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: Long-term follow up data of a randomized controlled multicentre study. <i>Journal of Autoimmunity</i> , 2015, 63, 88-93.	3.0	41
20	Combined Treatment with Antiviral Therapy and Rituximab in Patients with Mixed Cryoglobulinemia: Review of the Literature and Report of a Case Using Direct Antiviral Agents-Based Antihepatitis C Virus Therapy. <i>Case Reports in Immunology</i> , 2015, 2015, 1-5.	0.2	28
21	Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open-label, cohort study. <i>Hepatology</i> , 2015, 61, 1145-1153.	3.6	107
22	Impact of Immunogenetic IL28B Polymorphism on Natural Outcome of HCV Infection. <i>BioMed Research International</i> , 2014, 2014, 1-8.	0.9	16
23	Extrahepatic manifestations of chronic hepatitis C virus infection. <i>Digestive and Liver Disease</i> , 2014, 46, S165-S173.	0.4	218
24	Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia undergoing rituximab treatment. <i>Journal of Translational Medicine</i> , 2014, 12, 21.	1.8	14
25	Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: A prospective, controlled pilot study. <i>Digestive and Liver Disease</i> , 2014, 46, 833-837.	0.4	57
26	Hepatitis C-associated B-cell non-Hodgkin lymphomas: The emerging role of miRNA-26b. <i>Journal of Hepatology</i> , 2013, 59, 1362-1363.	1.8	8
27	Role of MicroRNA Profile Modifications in Hepatitis C Virus-Related Mixed Cryoglobulinemia. <i>PLoS ONE</i> , 2013, 8, e62965.	1.1	42
28	Hepatitis C virus-related mixed cryoglobulinemia: Is genetics to blame?. <i>World Journal of Gastroenterology</i> , 2013, 19, 8910.	1.4	20
29	HCV and Lymphoproliferation. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-8.	3.3	84
30	Hepatitis C virus infection in the immunocompromised host: a complex scenario with variable clinical impact. <i>Journal of Translational Medicine</i> , 2012, 10, 158.	1.8	14
31	The hepatitis C virus infection as a systemic disease. <i>Internal and Emergency Medicine</i> , 2012, 7, 201-208.	1.0	42
32	The Expanding Spectrum of Clinical Features in HCV-Related Mixed Cryoglobulinemia. , 2012, , 155-162.		3
33	Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. <i>Autoimmunity Reviews</i> , 2011, 10, 444-454.	2.5	186
34	A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection. <i>Autoimmunity Reviews</i> , 2011, 10, 714-719.	2.5	64
35	Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. <i>Blood</i> , 2010, 116, 335-342.	0.6	112
36	Hepatitis C virus RNA localization in human carotid plaques. <i>Journal of Clinical Virology</i> , 2010, 47, 72-75.	1.6	127

#	ARTICLE	IF	CITATIONS
37	HBV and HCV chronic infection: Autoimmune manifestations and lymphoproliferation. <i>Autoimmunity Reviews</i> , 2008, 8, 107-111.	2.5	32
38	Extrahepatic Manifestations of Hepatitis C Virus Infection. <i>Clinics in Liver Disease</i> , 2008, 12, 611-636.	1.0	75
39	Hepatitis C virus (HCV) infection: A systemic disease. <i>Molecular Aspects of Medicine</i> , 2008, 29, 85-95.	2.7	80
40	Association of t(14;18) translocation with HCV infection in gastrointestinal MALT lymphomas. <i>Journal of Hepatology</i> , 2008, 49, 170-174.	1.8	31
41	Association between persistent lymphatic infection by hepatitis C virus after antiviral treatment and mixed cryoglobulinemia. <i>Blood</i> , 2008, 111, 2943-2945.	0.6	24
42	HCV infection facilitates asymptomatic carotid atherosclerosis: preliminary report of HCV RNA localization in human carotid plaques. <i>Digestive and Liver Disease</i> , 2007, 39, S55-S60.	0.4	63
43	Effect of chronic hepatitis C virus infection on inflammatory lipid mediators. <i>Digestive and Liver Disease</i> , 2007, 39, S76-S82.	0.4	10
44	Improvement in liver cirrhosis after treatment of HCV-related mixed cryoglobulinemia with rituximab. <i>Digestive and Liver Disease</i> , 2007, 39, S129-S133.	0.4	18
45	B-cells and mixed cryoglobulinemia. <i>Autoimmunity Reviews</i> , 2007, 7, 114-120.	2.5	61
46	Hepatitis C virus-related lymphoproliferative disorders: An overview. <i>World Journal of Gastroenterology</i> , 2007, 13, 2467.	1.4	109
47	Association between mixed cryoglobulinemia, translocation (14;18), and persistence of occult HCV lymphoid infection after treatment. <i>Hepatology</i> , 2006, 43, 1166-1167.	3.6	35
48	Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2004, 33, 355-374.	1.6	449
49	Enhanced TH1 cytokine production in hepatitis C virus-infected patients with mixed cryoglobulinemia: understanding the pathological issues. <i>Journal of Hepatology</i> , 2004, 41, 1045-1049.	1.8	12
50	Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation. <i>Blood</i> , 2003, 102, 1196-1201.	0.6	99
51	Prevalence of <i>bcl-2</i> Rearrangement in Patients with Hepatitis C Virus-Related Mixed Cryoglobulinemia with or without B-Cell Lymphomas. <i>Annals of Internal Medicine</i> , 2002, 137, 571.	2.0	185
52	Erectile Dysfunction and Hepatitis C Virus Infection. <i>JAMA - Journal of the American Medical Association</i> , 2002, 288, 698-699.	3.8	55
53	Hepatitis C virus core protein expression in human B-cell lines does not significantly modify main proliferative and apoptosis pathways. <i>Journal of General Virology</i> , 2002, 83, 1665-1671.	1.3	18
54	Relation between infection and autoimmunity in mixed cryoglobulinemia. <i>Current Opinion in Rheumatology</i> , 2000, 12, 53-60.	2.0	73

#	ARTICLE	IF	CITATIONS
55	T(14;18) translocation in chronic hepatitis C virus infection. <i>Hepatology</i> , 2000, 31, 474-479.	3.6	157
56	Prevalence of mixed infection by different hepatitis C virus genotypes in patients with hepatitis C virus-related chronic liver disease. <i>Translational Research</i> , 1999, 134, 68-73.	2.4	47
57	Extrahepatic manifestations of HCV infection: facts and controversies. <i>Journal of Hepatology</i> , 1999, 31, 369-376.	1.8	140
58	Hepatitis C virus persistence in human hematopoietic cells injected into SCID mice. <i>Hepatology</i> , 1998, 28, 211-218.	3.6	91
59	Lymphotropic Virus Infection of Peripheral Blood Mononuclear Cells in B-Cell Non-Hodgkin's Lymphoma. <i>Acta Haematologica</i> , 1997, 98, 89-94.	0.7	14
60	Relevance of inapparent coinfection by hepatitis B virus in alpha interferon-treated patients with hepatitis C virus chronic hepatitis. <i>Journal of Medical Virology</i> , 1997, 51, 313-318.	2.5	63
61	Hepatitis-C virus infection and cancer. , 1997, 71, 1113-1115.		15
62	Polymyositis, lung fibrosis, and cranial neuropathy in a patient with hepatitis C virus infection. <i>Arthritis and Rheumatism</i> , 1996, 39, 1074-1075.	6.7	36
63	Hepatitis C Virus Genotype Analysis in Patients with Type II Mixed Cryoglobulinemia. <i>Annals of Internal Medicine</i> , 1996, 124, 31.	2.0	153
64	Hepatitis C Virus Lymphotropism and Possible Pathogenetic Implications.. , 1996, , 251-259.		0
65	Hepatitis C virus infection of mononuclear cells from peripheral blood and liver infiltrates in chronically infected patients. <i>Journal of Medical Virology</i> , 1995, 47, 58-64.	2.5	84
66	Mixed cryoglobulinemia as a possible preneoplastic disorder. <i>Arthritis and Rheumatism</i> , 1995, 38, 1859-1860.	6.7	53
67	Inapparent hepatitis B virus infection and hepatitis C virus replication in alcoholic subjects with and without liver disease. <i>Hepatology</i> , 1994, 19, 577-582.	3.6	44
68	Hepatitis C virus infection in patients with non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 1994, 88, 392-394.	1.2	455
69	Cryoglobulinemia Membranoproliferative Glomerulonephritis Associated with Hepatitis C Virus. <i>American Journal of Nephrology</i> , 1993, 13, 300-304.	1.4	58
70	Infection of peripheral mononuclear blood cells by hepatitis C virus. <i>Journal of Hepatology</i> , 1992, 15, 382-386.	1.8	418